{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:26Z","timestamp":1787003426786,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-sensitivity C-reactive protein (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) patients and reducing the hs-CRP level may further benefit this population. We conduct this parallel design, randomized-controlled trial to assess the effectiveness of adjunct sodium tanshinone IIA sulfate (STS) therapy on circulating inflammation markers in CAD patients. Unstable angina or non-ST-elevation myocardial infarction patients with increased hs-CRP level were randomly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS injection (80\u2009mg, once daily for 14 consecutive days). The primary outcome was hs-CRP level. After the 14-day treatment, the experimental group (n\u2009=\u200935) exhibited significantly lower levels of hs-CRP than the control group (n\u2009=\u200935) (1.72 vs 3.20\u2009mg\/L, p\u2009=\u20090.0191). Lower levels of interleukin-6, monocyte chemotactic protein-1 (MCP-1), and soluble CD40 ligand were also observed in the experimental group. Angina symptoms were also better controlled in the experimental group. At 30 days after treatment completion, MCP-1 levels remained lower in the experimental group than in the control group (313.88 vs 337.91\u2009pg\/mL, p\u2009=\u20090.0078). No serious adverse events occurred. Our study demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs-CRP and other circulating inflammation markers in CAD patients. (Chictr.org number: ChiCTR-TRC-12002361).<\/jats:p>","DOI":"10.1038\/s41598-017-16980-4","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T09:38:01Z","timestamp":1512553081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sodium tanshinone IIA sulfate adjunct therapy reduces high-sensitivity C-reactive protein level in coronary artery disease patients: a randomized controlled trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Siming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"16980_CR1","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys, M. B. & Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. \n                           111, 1805\u20131812 (2003).","journal-title":"J. Clin. Invest."},{"key":"16980_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","volume":"103","author":"PM Ridker","year":"2001","unstructured":"Ridker, P. M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. \n                           103, 1813\u20131818 (2001).","journal-title":"Circulation."},{"key":"16980_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. \n                           342, 836\u2013843 (2000).","journal-title":"N. Engl. J. Med."},{"key":"16980_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.321.7255.199","volume":"321","author":"J Danesh","year":"2000","unstructured":"Danesh, J. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. \n                           321, 199\u2013204 (2000).","journal-title":"BMJ."},{"key":"16980_CR5","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1016\/j.ijcard.2013.07.113","volume":"168","author":"W Koenig","year":"2013","unstructured":"Koenig, W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int. J. Cardiol. \n                           168, 5126\u20135134 (2013).","journal-title":"Int. J. Cardiol."},{"key":"16980_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.7326\/0003-4819-151-7-200910060-00009","volume":"151","author":"DI Buckley","year":"2009","unstructured":"Buckley, D. I., Fu, R., Freeman, M., Rogers, K. & Helfand, M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann. Intern. Med. \n                           151, 483\u2013495 (2009).","journal-title":"Ann. Intern. Med."},{"key":"16980_CR7","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. \n                           359, 2195\u20132207 (2008).","journal-title":"N. Engl. J. Med."},{"key":"16980_CR8","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. \n                           350, 1495\u20131504 (2004).","journal-title":"N. Engl. J. Med."},{"key":"16980_CR9","doi-asserted-by":"publisher","unstructured":"Shang Q. H., Xu H. & Huang L. Tanshinone IIA: a promising natural cardioprotective agent. Evid. Based Complement. Alternat. Med. 716459, https:\/\/doi.org\/10.1155\/2012\/716459 (2012).","DOI":"10.1155\/2012\/716459"},{"key":"16980_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.041","volume":"220","author":"S Gao","year":"2012","unstructured":"Gao, S. et al. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. \n                           220, 3\u201310 (2012).","journal-title":"Atherosclerosis."},{"key":"16980_CR11","first-page":"16","volume":"39","author":"QL Wang","year":"2007","unstructured":"Wang, Q. L., Deng, X. J., Li, X. Q. & Chen, X. T. Effect of sodium tanshinone injection on CRP and D-dimer level in patients with unstable angina. J. N. Chin. Med. \n                           39, 16\u201317 (2007).","journal-title":"J. N. Chin. Med."},{"key":"16980_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/138920007780655450","volume":"8","author":"XY Yu","year":"2007","unstructured":"Yu, X. Y. et al. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr. Drug Metab. \n                           8, 325\u201340 (2007).","journal-title":"Curr. Drug Metab."},{"key":"16980_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0021-9150(99)00463-3","volume":"148","author":"JS Yudkin","year":"2000","unstructured":"Yudkin, J. S., Kumari, M., Humphries, S. E. & Mohamed-Ali, V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. \n                           148, 209\u2013214 (2000).","journal-title":"Atherosclerosis."},{"key":"16980_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/hq0102.102278","volume":"122","author":"M Namiki","year":"2002","unstructured":"Namiki, M. et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. \n                           122, 115\u2013120 (2002).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"16980_CR15","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/01.RES.81.3.448","volume":"81","author":"U Schonbeck","year":"1997","unstructured":"Schonbeck, U. et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. \n                           81, 448\u2013454 (1997).","journal-title":"Circ. Res."},{"key":"16980_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1161\/01.CIR.94.5.874","volume":"94","author":"LM Biasucci","year":"1996","unstructured":"Biasucci, L. M. et al. Elevated levels of interleukin-6 in unstable angina. Circulation. \n                           94, 874\u2013877 (1996).","journal-title":"Circulation."},{"key":"16980_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/01.CIR.0000049742.68848.99","volume":"107","author":"JA de Lemos","year":"2003","unstructured":"de Lemos, J. A. et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. \n                           107, 690\u2013695 (2003).","journal-title":"Circulation."},{"key":"16980_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/07853890.2010.546362","volume":"43","author":"B Pamukcu","year":"2011","unstructured":"Pamukcu, B., Lip, G. Y., Snezhitskiy, V. & Shantsila, E. The CD40-CD40L system in cardiovascular disease. Ann. Med. \n                           43, 331\u2013340 (2011).","journal-title":"Ann. Med."},{"key":"16980_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jjcc.2008.12.007","volume":"53","author":"E Zakynthinos","year":"2009","unstructured":"Zakynthinos, E. & Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. \n                           53, 317\u2013333 (2009).","journal-title":"J. Cardiol."},{"key":"16980_CR20","doi-asserted-by":"publisher","first-page":"225ra29","DOI":"10.1126\/scitranslmed.3007672","volume":"6","author":"AL Robertson","year":"2014","unstructured":"Robertson, A. L. et al. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci. Transl. Med. \n                           6, 225ra29 (2014).","journal-title":"Sci. Transl. Med."},{"key":"16980_CR21","first-page":"188","volume":"17","author":"XJ Li","year":"2009","unstructured":"Li, X. J. et al. Effects of tanshinone IIa on cytokines and platelets in immune vasculitis and its mechanism. J. Exp. Hematol. \n                           17, 188\u2013192 (2009).","journal-title":"J. Exp. Hematol."},{"key":"16980_CR22","first-page":"39","volume":"5","author":"CZ Li","year":"1984","unstructured":"Li, C. Z., Yang, S. C. & Zhao, F. D. Effects of tanshinone II-A sulfonate on thrombus formation, platelet and blood coagulation in rats and mice. Acta Pharmacol. Sin. \n                           5, 39\u201342 (1984).","journal-title":"Acta Pharmacol. Sin."},{"key":"16980_CR23","doi-asserted-by":"publisher","unstructured":"Shang, Q. H., Wang, H., Li, S. M. & Xu, H. The effect of sodium tanshinone IIA sulfate and simvastatin on elevated serum levels of inflammatory markers in patients with coronary heart disease: a study protocol for a randomized controlled trial. Evid. Based Complement. Alternat. Med. 756519, https:\/\/doi.org\/10.1155\/2013\/756519 (2013).","DOI":"10.1155\/2013\/756519"},{"key":"16980_CR24","first-page":"1135","volume":"7","author":"H Chen","year":"2009","unstructured":"Schaefer, E. J. et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol. \n                           95, 1025\u20131032 (2005).","journal-title":"Chin. J. Integr. Med. Cardio\/Cerebrovasc. Dis."},{"key":"16980_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.amjcard.2005.01.023","volume":"95","author":"EJ Schaefer","year":"2005","unstructured":"Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology\/World Health Organization task force on standardization of clinical nomenclature. Circulation. \n                           59, 607\u2013609 (1979).","journal-title":"Am. J. Cardiol."},{"key":"16980_CR26","unstructured":"Hamm, C. W. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. \n                           32, 2999\u20133054 (2011)."},{"key":"16980_CR27","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Chen, H. et al. Clinical study of unstable angina patients undergoing percutaneous coronary intervention treated with Chinese medicine for activating blood circulation and detoxification. Chin. J. Integr. Med. Cardio\/Cerebrovasc. Dis. \n                           7, 1135\u20131137 (2009).","journal-title":"Eur. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16980-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16980-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:11:11Z","timestamp":1671793871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16980-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16980"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-16980-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]},"assertion":[{"value":"6 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial received financial support from the Jiangsu Carefree Pharmaceutical Co., Ltd. The company was not involved in developing the study design, collecting or interpreting the data, writing the paper, or publishing the results related to this trial. All of the authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17451"}}